Biota Holdings Limited - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Biota Holdings Limited Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Biota Holdings Limited. The Group's principal activity is discovering and developing antiviral drugs. The Group's operation focuses on the development of Zanamivir, neuraminidase inhibitor for the treatment and prevention of influenza. The Group also develops the influenza diagnostics FLU and OIA and FLU A/B influenza diagnostics, marketed as part of the BioStar range. The Group commenced Phase IIa clinical trials of its human rhinovirus (HRV) drug for the prevention and treatment of one of the major causes of the common cold. It operates in Australia.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report